GlassScriptPhysician profile
Robin Solymanijam
NPI 1811180144
$4,064.42
in general payments reported to CMS, 2019-2025
22 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $851 · 2021: $160 · 2022: $33.16 · 2023: $1,089 · 2024: $687 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,018 · Education: $98.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.09 |
| Education | $98.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $973.09 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $795.23 | 2019-2025 | Airsupra, Fasenra |
| Amgen INC. | $398.48 | 2023-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $365.05 | 2019-2025 | Ofev, Jascayd |
| Genzyme Corporation | $332.93 | 2019-2025 | |
| Philips North America LLC | $206.37 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.39 | 2020-2024 | |
| Genentech USA, INC. | $121.28 | 2019-2023 | Xolair |
| Baxter Healthcare | $118.24 | 2023 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| United Therapeutics Corporation | $108.12 | 2019-2024 | Tyvaso |
| Advanced Respiratory, INC | $101.32 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $79.55 | 2019 | |
| Grifols USA, LLC | $67.45 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $34.96 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $33.16 | 2022 | |
| Alkermes, INC. | $29.27 | 2024 | Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $20.95 | 2020 | |
| Allergan, INC. | $18.64 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.72 | 2019 | |
| Pfizer INC. | $15.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Solymanijam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.